NY-INTANDEM-CAPITAL
11.6.2024 13:01:30 CEST | Business Wire | Press release
InTandem Capital Partners, LLC (“InTandem” or “the Firm”), a middle-market private equity firm focused exclusively on healthcare services, announced today the final closing of InTandem Capital Partners Fund III, LP (“Fund III” or “the Fund”), with $715 million in total capital commitments. Fund III closed above its original target of $650 million.
Consistent with its predecessor funds, Fund III will continue the Firm’s well-established strategy of making control investments in North American payor, provider, and pharmaceutical services businesses using an operationally intensive, hands-on value creation model. InTandem partners closely with founders, entrepreneurs and management teams to accelerate transformational growth.
Fund III secured commitments from a globally diversified group of existing and new investors, including leading endowments, foundations, family offices, healthcare and pension systems, and financial institutions. The Fund is already actively investing, having recently completed its third platform deal in Adams Clinical, a multi-site clinical research management organization focused on late-stage outpatient central nervous system trials.
“We are delighted and grateful for the success of the fundraising for Fund III,” said Elliot Cooperstone, Managing Partner of InTandem. “We view the strong support as a testament to the depth and experience of our team and firmwide reputation built over two decades of partnering with healthcare services entrepreneurs. My colleagues and I are committed to working with great determination to deliver compelling returns and reward the trust of our limited partners.”
“Our long-standing focus on the Healthcare Quintuple Aim – the simultaneous pursuit of enhanced patient experience, elevated provider experience, improved clinical outcomes, greater healthcare equity, and lower cost of care delivery – continues to resonate with institutional investors,” added Brad Coppens, Senior Partner of InTandem. “We believe that investment success is intrinsically linked to alignment with and promotion of the Healthcare Quintuple Aim.”
“We thank our longtime investors for their continued partnership and welcome our new investors joining us in Fund III,” said Lauren Mangino, Principal and Head of Investor Relations and Capital Formation at InTandem. “We appreciate the confidence our limited partners have placed in us. It is a powerful endorsement of InTandem’s investment strategy.”
Kirkland and Ellis LLP served as legal counsel for Fund III and Raymond James acted as placement agent.
About InTandem Capital Partners
InTandem Capital Partners is a private equity firm that invests in and helps accelerate the growth of select healthcare services companies. InTandem is focused on investing in businesses that align with the Healthcare Quintuple Aim – the simultaneous pursuit of enhanced patient experience, elevated provider experience, improved clinical outcomes, greater healthcare equity, and lower cost of care delivery. The Firm is comprised of former business executives and experienced investors, and is qualified to provide strategic, acquisition and operating expertise to help companies increase their value and their contribution to an improved healthcare system. InTandem provides support to the management of its portfolio companies and leverages its network of industry executives to augment its capabilities. For further information, visit: www.intandemcapital.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611630040/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ATLAS Infrastructure Invests in H2O America, Backs Long-Term Growth Strategy10.3.2026 18:29:00 CET | Press release
ATLAS anchors H2O America’s equity raise and establishes new substantial shareholdingUpsized transaction highlights strong market support for H2O’s long-term strategy and sector leading growth outlookH2O’s organic growth fully equity funded into 20281 ATLAS Infrastructure (“ATLAS”) is a specialist Global Listed Infrastructure investor managing funds on behalf of long-term infrastructure clients. Following the recent equity placement, ATLAS’s actively managed accounts hold ~10.8% voting and economic interest in H2O America (“H2O”). ATLAS was pleased to support H2Os long‑term strategy to invest in local water and wastewater utility operations through our participation in the recent equity raise. ATLAS recognises the disciplined approach from H2O management which focuses on organic investment in existing businesses alongside targeted and accretive transactions such as the acquisition of Quadvest which materially expands H2O’s regulated water footprint in a premium high‑growth jurisdiction
TIXiMED Announces Promising Preclinical Data: Oral TIX100 Prevents Weight Regain After GLP-1 Cessation in Obesity Model10.3.2026 18:22:00 CET | Press release
TIX100 prevented weight regain in mice after semaglutide discontinuation Supports potential role as oral weight maintenance therapy following GLP-1 Receptor Agonist (GLP-1) treatment, addressing a major challenge in long-term obesity management TIXiMED, Inc., a clinical-stage pharmaceutical company developing a novel oral therapy targeting thioredoxin-interacting protein (TXNIP) for diabetes and metabolic disorders, is pleased to highlight new research by investigators at the University of Alabama at Birmingham (UAB) Comprehensive Diabetes Center. The study demonstrates that its oral compound, TIX100, effectively prevents weight rebound following discontinuation of GLP-1 treatment in a mouse model of diet-induced obesity. In the study, mice treated with semaglutide experienced significant weight loss of over 13% body weight during a 2-week treatment period while continuing a high-fat diet. Upon discontinuation of semaglutide, untreated mice rapidly regained 14% of their body weight, mi
Svante and Integrated Packaging Company Advance U.S. Biogenic CDR Project to Feasibility10.3.2026 14:57:00 CET | Press release
The bioenergy with carbon capture (BECCS) project aims to remove more than 500,000 tonnes per year of biogenic CO2 emissions from a U.S. paper mill’s recovery boiler Svante Development Inc. is co-investing to advance the project The project will generate high-quality carbon dioxide removal (CDR) credits to market to Voluntary Carbon Market (VCM) buyers. Svante Technologies Inc. (“Svante”) announced today that its bioenergy with carbon capture and storage (BECCS) project at a paper mill in the Southeast U.S. has progressed to the feasibility study phase. The project is being developed in partnership with an integrated sustainable packaging company, following an extensive screening and pre-feasibility study conducted across several of the partner’s mills. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310319382/en/ During the feasibility study phase, the companies will complete further engineering and design activities, cos
Forbes 40th Annual World’s Billionaires List10.3.2026 14:43:00 CET | Press release
Elon Musk Is World’s Richest Person Ever Recorded Forbes releases its 40th-annual World’s Billionaireslist, the definitive ranking of the planet’s richest people. Wealth surged to unprecedented levels over the past year, with fortunes climbing at a record pace. This year’s list features 3,428 billionaires, the most since the list’s inception in 1987. The world’s wealthiest people are worth a record $20.1 trillion combined, up from $16.1 trillion in 2025. Elon Musktops the Billionaires list for the second year in a row and is the richest person ever recorded, worth an estimated $839 billion. His net worth skyrocketed by half of a trillion dollars from last year, thanks to a rise in the value of Tesla, and SpaceX which is aiming to go public in 2026. Musk is the first person ever recorded to reach the $800 billion mark, as he moves toward becoming the world’s first trillionaire. “It’s the year of the billionaire,” said Chase Peterson-Withorn, Forbes Senior Editor, Wealth. “The planet add
Adtran sets intra-data center benchmark with all-new ultra-low-power LiteWave800™ LPO module10.3.2026 14:00:00 CET | Press release
News summary: AI clusters and GPU fabrics demand massive capacity, yet traditional 800G optics increase energy consumption, heat and cost burdens Adtran’s LiteWave800™ introduces a new class of ultra-low-power, low-latency DR8 LPO modules built on a fully re-engineered design Breakthrough energy efficiency of 1pJ/bit enables greener, scalable intra-data center links for next-generation AI and cloud workloads Adtran today launched LiteWave800™, an ultra‑low‑power 800Gbit/s DR8 linear pluggable optics (LPO) module engineered to help data centers address the power, latency, thermal and bandwidth demands of modern AI and machine-learning (ML) workloads. As GPU clusters grow and short-reach links scale across dense server racks, operators need 800Gbit/s optics that deliver higher capacity within strict power and cooling limits. LiteWave800™ answers this challenge with a fully re-engineered architecture that significantly reduces energy consumption. Operating at just 1pJ/bit and consuming on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom